CRISPR Therapeutics AG
CRSP
$56.64
-$3.36-5.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.81% | -0.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.81% | -0.34% | |||
| Cost of Revenue | 18.28% | 0.84% | |||
| Gross Profit | -18.45% | -0.85% | |||
| SG&A Expenses | 8.67% | -10.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.06% | -0.76% | |||
| Operating Income | -17.19% | 0.76% | |||
| Income Before Tax | -22.85% | 48.94% | |||
| Income Tax Expenses | -0.81% | -52.09% | |||
| Earnings from Continuing Operations | -22.71% | 48.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.71% | 48.96% | |||
| EBIT | -17.19% | 0.76% | |||
| EBITDA | -16.83% | 0.62% | |||
| EPS Basic | -17.60% | 51.33% | |||
| Normalized Basic EPS | -17.73% | 9.09% | |||
| EPS Diluted | -17.19% | 51.25% | |||
| Normalized Diluted EPS | -17.73% | 9.09% | |||
| Average Basic Shares Outstanding | 4.34% | 4.86% | |||
| Average Diluted Shares Outstanding | 4.34% | 4.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||